Editas Medicine, a Cambridge, MA-based genome editing company, secured a $43m Series A financing.
The round was led by Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.
Founded by Feng Zhang, Ph.D., George Church, Ph.D., Jennifer Doudna, Ph.D., Keith Joung, M.D., Ph.D., and David Liu, Ph.D., Editas leverages patent filings and intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements to develop viable human therapeutic products.
The management team includes Kevin Bitterman, Ph.D., interim president, Alexis Borisy, director, Alexandra Glucksmann, Ph.D., interim chief operating officer and former founding employee and SVP of research and development at Cerulean Pharma, and Lou Tartaglia, Ph.D., interim chief scientific officer and partner, Third Rock Ventures.
The board of directors is composed of Mr. Borisy; Douglas Cole, M.D., general partner, Flagship Ventures; and Terry McGuire, co-founder and general partner, Polaris Partners.